Comment from vaishali kurdikar

Comments on Draft Guidance: “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection” (March 2026) **General Position** We appreciate FDA’s efforts in issuing this guidance, which reflects alignment with ICH Q9 and Q10 and promotes a science- and risk-based approach. The guidance is a positive step toward strengthening pharmaceutical quality systems and patient-centric decision making. --- Positive Aspects Management Accountability (Section III.A(4), IV.B) Strongly support executive management signatory and oversight. This reinforces that quality is a management responsibility and promotes resource allocation and quality culture. Risk-Based Approach (Section III.A(7), IV) Emphasis on patient- and product-focused risk assessment is appropriate and aligned with global expectations. Systemic Evaluation (Section IV): Encouragement to assess observations holistically rather than individually will help identify underlying quality system gaps. Root Cause Rigor (Section IV.C) Focus on true root cause and avoidance of bias is commendable and addresses a key industry gap. CAPA Effectiveness (Section IV.E) Emphasis on effectiveness checks supports sustainable remediation and continuous improvement. Structured Response Format (Section III.A) Clear expectations for response structure will improve consistency and communication with FDA. Areas for Consideration / Improvement 15-Day Timeline (Section III.D) Expectation to provide comprehensive investigation, root cause, risk assessment, and CAPA within 15 business days may not be feasible for complex operations. Recommendation: Allow phased responses (initial containment + subsequent detailed updates). Single Comprehensive Response (Section III.D): Limiting to a single response may restrict submission of scientifically robust data. Recommendation: Allow modular or staged submissions without regulatory disadvantage. distributed Product Risk Assessment (Section III.A(7)): In CDMO models, data and decision authority often reside with the MAH. *Recommendation:* Clarify roles and responsibilities between CDMO and MAH. Scope of Systemic Investigations (Section IV) Expansion across products and clients may be challenging due to confidentiality and operational boundaries. *Recommendation:* Provide risk-based criteria for defining investigation scope. Root Cause Expectations (Section IV.C): Confirmed root cause may not be achievable within short timelines. *Recommendation:* Allow interim root cause with later confirmation. CAPA Commitments (Section IV.D): Early detailed CAPA may lead to premature or evolving commitments. *Recommendation:* Permit staged CAPA aligned with investigation progress. CAPA Effectiveness (Section IV.E): Demonstration of effectiveness may not be feasible at initial response stage. *Recommendation:* Allow post-response effectiveness verification commitments. Documentation Burden (Section III.A): Extensive documentation requirements may shift focus from remediation to document preparation. *Recommendation:* Encourage concise, risk-based documentation. CDMO-Specific Considerations (General): Guidance does not address shared responsibilities between CDMO and MAH. *Recommendation:* Include clarification for CDMO operating models. Conclusion The guidance provides a strong, modern framework for FDA 483 responses. With added flexibility and clarification in key areas, it can further enhance practical implementation while maintaining its intent to strengthen quality systems and protect patient safety.